A Phase 2 interventional study of IA Carboplatin + IA Caelyx and IA Carboplatin + IA Etoposide Phosphate in Glioblastoma Multiforme and Relapse, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by Université de Sherbrooke · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Glioblastoma with a site in Canada — 17 open to participants now, 34 under way, 5 of them phase 3. Glioblastoma · Canada.
Among the 118 studies in Glioblastoma with a site in Canada, this one is the 44th largest by planned enrollment of the 111 interventional ones that give a count, is one of 8 that started in 2025, is one of 33 in phase 2, reaches primary completion later than 16 of the 33 other live ones, and was the 111th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →17 of the 118 studies in Glioblastoma with a site in Canada are open now. Recruiting first, the newest first:
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 65+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
Nationwide Children's Hospital · Sites in Canada, United States, Australia and 3 more countries
Ages 1–21 · Healthy volunteers
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Rigel Pharmaceuticals · Sites in Canada, United States, Australia and 4 more countries
Ages 12–39
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 47 · Phase 3 30 · Phase 4 1
First in 1994; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.
Median enrollment 74 across the 111 interventional studies, 36 across the 6 observational. Of the 75 that completed or were terminated, 24 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 118 have an industry lead sponsor. The 10 most frequent:
Université de Sherbrooke is the lead sponsor of 298 studies on the registry; 67 are open to participants now.
Université de Sherbrooke has 2 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
9 of the studies in Glioblastoma with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT04765098AHS Cancer Control AlbertaTamoxifen Versus Etoposide After First Recurrence in GBM Patients | 2026-12 |
| NCT05941507LigaChem Biosciences, Inc.A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | 2027-01 |
| NCT06356883Université de SherbrookeIntraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma | 2027-04 |
| NCT06850766Ottawa Hospital Research InstituteThe Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma | 2027-05 |
Add all 9 to your calendar (.ics) → With an account.
Among the 118 studies in Glioblastoma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is inevitable. At relapse, there is no consensus regarding the optimal therapeutic strategy. The rationale behind the fact that limited chemotherapy agents are available in the treatment of malignant gliomas is related to the blood-brain barrier (BBB), which impedes drug entry to the brain. Intraarterial (IA) chemotherapy allows to circumvent this. Using IA delivery of carboplatin, can produce responses in 70% of patients for a median PFS of 5 months. Median survival from study entry was 11 months, whereas the overall survival (OS) 23 months. How can the OS and PFS be improved? By combining chemotherapeutic agents with different mechanisms of action.
Study design: In this phase II trial, treatment will be offered at relapse. Surgery will be performed for cytoreduction if it is warranted, followed with a combination IA carboplatin + IA Cealyx (liposomal doxorubicin) or IA carboplatin + IA etoposide phosphate. Toxicity will be assessed according to the NCIC common toxicity criteria. Treatment will consist in either IA carboplatin (400 mg/m\^2) + IA Cealyx (30 mg/m\^2) or IA carboplatin (400 mg/m\^2) + IA etoposide phosphate (400 mg/m\^2) every 4-6 weeks (1 cycle). Up to twelve cycles will be offered.
Outcome measurements: Tumor response will be evaluated using the RANO criteria by magnetic resonance imaging monthly. Primary outcome will PFS and tumor response. Secondary outcome will include median OS, toxicity, quality of life (QOL), neurocognition (NC).
Putting together these data will allow to correlate clinical and radiological response to QOL and NC.
BACKGROUND - Glioblastoma (GBM) is the most common and aggressive primary brain tumour in adults. The standard first-line treatment for these tumours features maximized surgery followed by radiation with concomitant and adjuvant temozolomide. The overall survival (OS) and progression-free survival (PFS) observed in the clinic with this paradigm are only 14.6 and 6, 9 months respectively. One of the challenges in the treatment of this neoplasm stems from the severe tumour heterogeneity which translates into unpredictable treatment response. As a result, newly diagnosed tumours inevitably relapse after the standard first-line treatment, which is called the Stupp protocol which combines radiation therapy and oral temozolomide. When recurrence occurs, if the patient's functional status is adequate, this will mandate other therapeutic strategies. Interestingly, results obtained in most studies in this setting have been so marginal that there is literally no recognized optimal second and third line of treatment. Admittedly, the access to active therapies is greatly limited by the presence of the blood-brain barrier (BBB), which severely reduces the chemotherapy entry to the CNS.
When one realizes the extensiveness of the vascular network supplying the brain, it appears obvious that a global delivery strategy via this vascular network as a delivery corridor is credible and legitimate. The importance of this vascular system has already been detailed by Bradbury; the author claims that the entire network covers an area of 12 m2/g of cerebral parenchyma. To understand the extensiveness of the cerebral vascularization in a more prosaic way, let us just consider that the brain receives about 20% of the total systemic circulation although it weighs less than 3% of the total body weight.
The access to a patient's cerebral vascular network is technically easy and actually repeatedly performed in the clinic on a regular basis. Via a simple puncture to access the femoral artery, a catheter can be introduced and navigated intraarterially to reach one of the four major cerebral arteries. Once in the target vessel, a therapeutic agent can be administered via the catheter, that is later withdrawn at the conclusion of the procedure. The CIAC allows the construct of a regional chemotherapeutic distribution paradigm within the area irrigated by the targeted vessel.
An increase in the local plasma peak concentration of the drug yields a significantly improved AUC (concentration of drug according to the time) through the first pass effect. This consequently translates in an increased local exposure of the target tissue to the therapeutic agent. Interestingly, as our lab as shown, it is also accompanied by a decreased systemic drug distribution, hence reducing systemic toxicity and potential side effects. Consequently, the therapeutic concentration at the targeted tumour cells is increased by a 3.5 to 5-fold factor. This procedure is performed in the angiographic suite under local anesthesia and typically lasts around 45 minutes.
The IA procedure is a very safe procedure. Indeed, this procedure has been used at our institution for over 15 years using various chemotherapeutic agents and thus have precise statistics on the risks and complications. Indeed, 722 different patients have been treated adding up to 3600 procedures and have compiled the following events. During the MRI that followed the IA infusion, 66 complications were identified (1.84%), 27 of which were associated to symptoms (0.75%). During the infusion, 39 episodes of seizures occurred (1.08%), all of which were successfully controlled with anti-seizure medication. Moreover, a significant reduction in white, red or platelet blood cell count occurred in 52 patients during the treatment phase (7.2%). This study will investigate the efficacy of using combined chemotherapeutic agents described above. Our team currently uses intraarterial (IA) infusion to alleviate the effects of the BBB. This delivery strategy was shown to be well tolerated, triggered very few discomforts and side effects, and significantly improved survival. So much so, that it is nowadays considered a standard of care for relapsing tumours in our institution.
Like cisplatin, carboplatin is a molecule made of a platinum atom surrounded in a plane by two ammonia groups and two other ligands in the cis position. Unlike the chloride atoms found in cisplatin, the ligands in carboplatin are esther functional groups that form a ring structure. As such, carboplatin is more stable, causes less vomiting and is less neurotoxic, less ototoxic and less nephrotoxic. Carboplatin's exact mechanism of action remains unclear. However, it is well known that carboplatin is activated inside the cell into reactive platinum species. These reactive complexes react with DNA bases to create inter- and intrastrand crosslinks which prevent cell division by hindering DNA synthesis.
At our institution, carboplatin is the primary chemotherapeutic agent for IA infusions and yields positive tumour responses in 70% of patients for a median PFS of 5 months. Although interesting, there is obviously room for improvement in the care of these patients. Hence the current proposal.
For patients in which carboplatin fails, other chemotherapeutics are chosen arbitrarily from a list of agents available for IA infusion. As such, our team has successfully treated relapsing GBM patients with IA delivery of methotrexate, melphalan, etoposide phosphate or Caelyx (liposomal doxorubicin). At the heart of the present study, carboplatin, which will be combined with either one of two agents found to be ideally suited in this setting: Caelyx (liposomal doxorubicin) or etoposide phosphate.
Doxorubicin is an anthracycline, an antineoplastic antibiotic developed from Streptomyces peucetius subsp. Cassius. It is a very potent antitumour agent and is considered one of the most active antineoplastic drugs developed to date. Its effect is produced via different mechanisms: DNA binding and cross-linking, interference with DNA strand separation, inhibition of RNA polymerase, inhibition of topoisomerase II, formation of free radicals and membrane peroxidation have all been suggested.
In vitro studies in malignant glial cell lines have demonstrated that doxorubicin induces a halt in cell growth within 24 hours, and results in apoptosis within 48 hours. It has been identified as one of the most potent chemotherapeutic drugs against malignant glioma cell lines in vitro. However, in vivo, the use of doxorubicin is limited by its inability to cross the BBB.
Doxorubicin is rapidly distributed in the body tissues, and binds to plasma protein and cell membranes. The clinical application of this agent is unfortunately limited by its dose-related side effects such as cardiotoxicity and myleotoxicity.
Caelyx is a chlorhydrate of doxorubicin encapsulated within a pegylated liposome. The liposomal formulation of doxorubicin (Caelyx) exhibits an altered pharmacokinetic profile favouring the use of this drug formulation in brain tumour treatment. It has a longer terminal half-life than free doxorubicin, and reaches greater concentration in the tumour. Because of a decreased uptake by the reticuloendothelial system, the drug remains in circulation much longer. This seems to be especially true in glioblastoma, where it tends to accumulate in significant concentration due to the increase in neovascularisation. This has been shown in experimental settings, as well as in the clinic. Interestingly, because of its altered pharmacokinetic properties, it also presents a reduced toxicity profile. The liposomal formulation of doxorubicin causes less myelosuppression, nausea, vomiting and alopecia than standard doxorubicin. The cardiotoxicity is also reduced.
However, even with the greater accumulation of the drug in the tumour cells, its rate of BBB penetration when administered via IV infusion remains a limiting factor. Indeed, it is too low to yield a significant concentration accumulation within the tumour site to produce a therapeutic benefit.
Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is rapidly and completely converted to the parent compound after intravenous dosing. The pharmacokinetic profile of either etoposide or etoposide phosphate is identical. Toxicity and clinical activity are also the same. Since etoposide phosphate is water soluble, solutions of up to 20 mg/mL can be prepared. However, in high doses, it can only be given as a 5-minute bolus, in small volumes and as a continuous infusion. Furthermore, it is not formulated with polyethylene glycol, polysorbate 80 (Tween; ICI Americas, Wilmington, DE), and ethanol, and does not cause acidosis when given at high doses. The easier-to-use etoposide phosphate represents an improved formulation of etoposide.
Classically, etoposide must be diluted prior to use with sodium chloride (0.9% w/v) or glucose (5% w/v) solutions to concentration of 0.2 mg/mL (i.e., 1 ml of concentrate in 100 ml of vehicle) up to 0.4 mg/mL (i.e., 2 ml of concentrate in 100 ml of vehicle). Evidently, this cannot be something considered in a setting of IA administration, as the volume administered would be excessive. Hence, the use of etoposide phosphate, for which 100-fold increased concentration can be prepared in a volume accessible for an IA administration: 200 cc.
STUDY DESIGN - This clinical trial will be an open label randomized phase II study in which intraarterial administration of carboplatin (400 mg/m2) combined with Caelyx (30 mg/m2) will be compared with intraarterial administration of carboplatin (400 mg/m2) combined with etoposide phosphate (400 mg/m2). Patients that have failed the standard first line of treatment (Stupp protocol) and that are diagnosed with recurrent GBM will be randomly distributed to one of the two second-line treatment paradigms using the block randomization method. Each recruited patient will undergo maximal resection before beginning treatments. Treatment cycles will be administered on a monthly basis until a progression is identified on the magnetic resonance imaging (MRI) scan or until a total of 12 cycles have been completed. The cohort will count 120 patients that will be divided into two groups of 60 patients receiving one of the two chemotherapeutic combinations. As to which of the two combinations will be best remains to be determined. For that reason, data from our latest published clinical trial and patients treated with intraarterial carboplatin at our institution will be used as benchmarks for baseline comparisons (OS of 11 months and PFS of 5 months from study entry).
AIM - By using carboplatin in combination with Caelyx or etoposide phosphate in the setting of an IA infusion, our intention is to optimally deliver carboplatin-based chemotherapy combinations to the brain beyond the BBB, and more specifically to the tumour cells.
HYPOTHESES - In patients treated with either combination, our prediction is that this will lead to an improved tumour response and control rate, with minimal impact on the quality of life. Our preliminary clinical data seems to support this hypothesis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Haematopoietic parameters at recruitment:
Hepatic parameters at recruitment:
Renal parameters at recruitment:
Written obtained.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated with IA carboplatin + IA liposomal doxorubicin on each cycle (4-6 weeks), for up to 12 cycles.
Drug: IA Carboplatin + IA Caelyx
Participants will be treated with IA carboplatin + IA etoposide phosphate on each cycle (4-6 weeks), for up to 12 cycles.
Drug: IA Carboplatin + IA Etoposide Phosphate
Intraarterial infusion of carboplatin combined with liposomal doxorubicin
Intraarterial infusion of carboplatin combined with etoposide phosphate
Tumor Response on MRI using the RANO Criteria
T1 +/- contrast agent , T2 and FLAIR
Time frame: Every 4 weeks until progression per RANO criteria; up to 12 months
Progression-free Survival
Time elapsed between study entry and progression
Time frame: When radiological progression per RANO criteria is reported; through study completion, an average of 6 months
Median overall survival
Time elapsed between initial diagnosis and death
Time frame: When death is reported; through study completion, an average of 2 years
Treatment-related toxicity
Recording of adverse events
Time frame: When hematological or non-hematological events are reported, through study completion, an average of 2 year
Per treatment quality of life assessment
SNAS questionnaire (Sherbrooke neuro assessment scale for quality of life). Scale ranges from 30 to 120; the lower scores indicate better quality of life
Time frame: Every 4 weeks until progression per RANO criteria; up to 12 months
Incidence of treatment related Neurocognitive decline
MOCA questionnaire (Montreal Cognitive Assessment)
Time frame: Every 4 weeks until progression per RANO criteria; up to 12 months
Plan to share: No
Start is estimated for Aug 2025; primary completion for Apr 2027, 20 months later.
Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 20 months is below that.
Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.